The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.

• Collection of epidemiological data on non-high-risk APL patients aged ≤ 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status…).
• Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients.
• Documentation of Minimal Residual Disease (MRD).
• Correlation of clinical outcomes with the chosen therapy.
• Validation of published prognostic factors and identification of new prognostic factors

Inclusion Criteria:

• Newly-diagnosed APL (either de novo or therapy-related) based on cytologic criteria and confirmed by the presence of the t(15;17) translocation and/or by the detection of the fusion transcript PML/RARα.
• Non-high-risk APL (White Blood Count < 10000/μl at presentation)
• Age ≤ 70 years

Exclusion Criteria:

• Relapsed APL
• Newly-diagnosed High-risk APL (White Blood Count > 10000/μl at presentation)
• Age > 70 years

French patients with newly-diagnosed de novo or therapy-related non-high-risk APL (White Blood Count < 10000/μl) aged ≤ 70 years.